Stockscreener 앱 받기
0.95
2.68%
-0.0262
Rallybio Corp 주식(RLYB)의 최신 뉴스
Rallybio stock plunges to 52-week low, touches $0.94 - Investing.com
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase - Investing.com
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase By Investing.com - Investing.com UK
US Penny Stocks To Consider In December 2024 - Simply Wall St
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio Corporation Announces Promising RLYB212 and RLYB332 Preclinical Data at 66th American Society of Hematology Annual Meeting - Marketscreener.com
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66 - Business Wire
Rallybio's ASH Data Shows Breakthrough Potential in Blood Disorder Treatments, Strong Preclinical Results - StockTitan
Rallybio price target lowered to $7 from $8 at JMP Securities - Yahoo Finance
Rallybio (NASDAQ:RLYB) Earns Buy Rating from HC Wainwright - Defense World
Rallybio shares retains Buy rating on treatment potential By Investing.com - Investing.com Australia
Rallybio shares retains Buy rating on treatment potential - Investing.com
Rallybio : RLYB116 Clinical Program Update – Harnessing the Power of C5 Inhibition - Marketscreener.com
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 - Business Wire
Rallybio advances Phase 2 trial for rare pregnancy condition By Investing.com - Investing.com Nigeria
Rallybio Flat On Release Of New Findings - MENAFN.COM
Rallybio Flat on Release of New Findings - Baystreet.ca
Rallybio advances Phase 2 trial for rare pregnancy condition - Investing.com
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women - Business Wire
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.01% - MSN
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference - Marketscreener.com
Rallybio's SWOT analysis: rare disease biotech stock advances FNAIT treatment - Investing.com
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor - Business Wire
Rallybio to Host Key Webcast on RLYB116 C5 Inhibitor Development Updates - StockTitan
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women - Clinical Trials Arena
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 - Business Wire
Rallybio Launches Phase 2 Trial for Groundbreaking Pregnancy Treatment RLYB212 - StockTitan
Rallybio stock hits 52-week low at $0.96 amid market challenges - Investing.com India
FMR LLC Acquires Shares in Rallybio Corp - GuruFocus.com
HC Wainwright Issues Pessimistic Forecast for Rallybio (NASDAQ:RLYB) Stock Price - Defense World
Staff cuts help New Haven-based biotech Rallybio reduce 3Q loss - Hartford Business Journal
Rallybio Co. (NASDAQ:RLYB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - BioSpace
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech - PharmaVoice
Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada
Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada
Rallybio advances novel FNAIT prevention trial - Investing.com India
Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks
Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire
2.88%
2.65%
자본화:
|
볼륨(24시간):